Table 1. Characteristics of patients... | American Society of Hematology

Table 1.

Characteristics of patients with hepatitis C virus infection

Patient	Age (y)	Gender	ALT/AST	Viral load	RT-PCR	Geno type	Liver histology	Duration of disease (y)	Prior Treatment
1	49	M	108/99	1.2 × 10⁴	Quant.	3a	Cirrhosis	Unknown	IFN-α
2	48	M	183/137	3.9 × 10⁶	Quant.	3a	Cirrhosis	28	None
3	48	F	78/57	3.5 × 10⁵	Quant.	3a	Cirrhosis	25	None
4	51	M	107/92	10 × 10⁶	Quant.	3a	Cirrhosis	20	None
5	49	M	93/89	3.2 × 10⁶	Quant.	1a	Fibrosis	30	None
6	51	M	84/61	2.2 × 10⁶	Quant.	1b	Fibrosis	30	None
7	62	F	73/76	1.5 × 10⁴	Quant.	4c	Fibrosis	20	IFN-α+Ribavirin
8	40	F	70/34	1.8 × 10⁴	Quant.	1d	Cirrhosis	25	None
9	54	F	70/58	1 × 10⁶	Quant.	2a	Cirrhosis	30	None
10	52	F	47/33	3 × 10⁵	Quant.	1b	Fibrosis	30	None
11	35	M	164/130	5 × 10⁶	Quant.	1a/1b	Fibrosis	30	None
12	48	M	238/99	3 × 10⁶	Quant.	1a	Fibrosis	6	IFN-α
13	45	M	Unknown	7.5 × 10⁵	Quant.	1a	Fibrosis	25	IFN-α+Ribavirin
14	41	M	36/24	Pos	Qual.	Unknown	Cirrhosis	20	IFN-α
15	52	M	115/68	2.2 × 10⁴	Quant.	1a	Fibrosis	30	IFN-α+Ribavirin
16	50	F	36/34	Neg.	Qual.	3a	Unknown	22	IFN-α+Ribavirin
17	49	F	10/16	Neg.	Qual.	1b	Unknown	3	IFN-α+Ribavirin
18	45	F	15/26	Neg.	Qual.	1a	Unknown	20	IFN-α+Ribavirin
19	46	M	29/21	Neg.	Qual.	2	Normal	32	IFN-α
20	48	M	15/16	Neg.	Quant.	2b	Fibrosis	10	IFN-α+Ribavirin
21	53	F	15/22	Neg.	Quant.	Unknown	Unknown	4	IFN-α+Ribavirin
22	45	F	Norm.	Neg.	Quant.	1a, 1b	Fibrosis	7	IFN-α+Ribavirin
23	50	M	Norm.	Neg.	Quant.	2b	Unknown	32	IFN-α+Ribavirin

Patient	Age (y)	Gender	ALT/AST	Viral load	RT-PCR	Geno type	Liver histology	Duration of disease (y)	Prior Treatment
1	49	M	108/99	1.2 × 10⁴	Quant.	3a	Cirrhosis	Unknown	IFN-α
2	48	M	183/137	3.9 × 10⁶	Quant.	3a	Cirrhosis	28	None
3	48	F	78/57	3.5 × 10⁵	Quant.	3a	Cirrhosis	25	None
4	51	M	107/92	10 × 10⁶	Quant.	3a	Cirrhosis	20	None
5	49	M	93/89	3.2 × 10⁶	Quant.	1a	Fibrosis	30	None
6	51	M	84/61	2.2 × 10⁶	Quant.	1b	Fibrosis	30	None
7	62	F	73/76	1.5 × 10⁴	Quant.	4c	Fibrosis	20	IFN-α+Ribavirin
8	40	F	70/34	1.8 × 10⁴	Quant.	1d	Cirrhosis	25	None
9	54	F	70/58	1 × 10⁶	Quant.	2a	Cirrhosis	30	None
10	52	F	47/33	3 × 10⁵	Quant.	1b	Fibrosis	30	None
11	35	M	164/130	5 × 10⁶	Quant.	1a/1b	Fibrosis	30	None
12	48	M	238/99	3 × 10⁶	Quant.	1a	Fibrosis	6	IFN-α
13	45	M	Unknown	7.5 × 10⁵	Quant.	1a	Fibrosis	25	IFN-α+Ribavirin
14	41	M	36/24	Pos	Qual.	Unknown	Cirrhosis	20	IFN-α
15	52	M	115/68	2.2 × 10⁴	Quant.	1a	Fibrosis	30	IFN-α+Ribavirin
16	50	F	36/34	Neg.	Qual.	3a	Unknown	22	IFN-α+Ribavirin
17	49	F	10/16	Neg.	Qual.	1b	Unknown	3	IFN-α+Ribavirin
18	45	F	15/26	Neg.	Qual.	1a	Unknown	20	IFN-α+Ribavirin
19	46	M	29/21	Neg.	Qual.	2	Normal	32	IFN-α
20	48	M	15/16	Neg.	Quant.	2b	Fibrosis	10	IFN-α+Ribavirin
21	53	F	15/22	Neg.	Quant.	Unknown	Unknown	4	IFN-α+Ribavirin
22	45	F	Norm.	Neg.	Quant.	1a, 1b	Fibrosis	7	IFN-α+Ribavirin
23	50	M	Norm.	Neg.	Quant.	2b	Unknown	32	IFN-α+Ribavirin

Chronic HCV infection (patients 1-15), resolved HCV infection (patients 16-23).

ALT/AST indicates alanine amino transferase/aspartate amino transferase; RT-PCR, reverse transcription–polymerase chain reaction; IFN-α, interferon α; HCV, hepatitis C virus.

View Large

This Feature Is Available To Subscribers Only